Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Dabrafenib + Trametinib salivary gland carcinoma predicted - sensitive detail...
CD274 positive Pembrolizumab salivary gland carcinoma predicted - sensitive detail...
BRAF V600E Vemurafenib salivary gland carcinoma predicted - sensitive detail...
HRAS act mut Tipifarnib salivary gland carcinoma sensitive detail...
PTEN L152P PTEN neg AZD8186 salivary gland carcinoma resistant detail...
PTEN L152P PTEN neg GSK2636771 salivary gland carcinoma resistant detail...
PTEN L152P PTEN neg Alpelisib salivary gland carcinoma resistant detail...
PTEN L152P PTEN neg Alpelisib + AZD8186 salivary gland carcinoma sensitive detail...
PTEN L152P PTEN neg Pictilisib salivary gland carcinoma sensitive detail...
FGFR2 Y375C RLY-4008 salivary gland carcinoma predicted - sensitive detail...
HRAS G13V PIK3CA E545K Tipifarnib salivary gland carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Unknown status CAN 0
NCT03146650 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer Active, not recruiting USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03749460 Phase Ib/II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Completed USA 0
NCT03942653 Phase II Goserelin + Pembrolizumab Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma Recruiting USA 0
NCT04832438 Phase II Carboplatin + Elraglusib 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma Withdrawn USA 0
NCT05010629 Phase II Carboplatin + Elraglusib 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Active, not recruiting USA 0
NCT05408845 Phase II Docetaxel + Trastuzumab Ado-trastuzumab emtansine Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer Recruiting USA 0
NCT05513365 Phase II Bicalutamide + Goserelin Bicalutamide + Dutasteride + Goserelin Phase II Dutasteride in Combination With CAB vs CAB in SDC (DUCT) Recruiting NLD 0
NCT05884320 Phase II Sacituzumab govitecan-hziy Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers Recruiting USA 0